Evidence map›Paper›PMID 35045871›Full record

ArticleMicrobiome2022

Metabolite-based dietary supplementation in human type 1 diabetes is associated with microbiota and immune modulation.

Kirstine J Bell, Sonia Saad, Bree J Tillett, Helen M McGuire, Sara Bordbar, Yu Anne Yap, Long T Nguyen, Marc R Wilkins, Susan Corley, Shannon Brodie and 9 more

Open access · goldAbstract readVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiome, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 3 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 3 syntheses or guidelines pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. [Gut microbiota dysbiosis in type 1 diabetes mellitus: Impacts, mechanisms, and interventions].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  15. Article
  16. Oral GAD65-Microorganisms · 2026
    Article
  17. Review
  18. Article
  19. Article
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 3 countries.

Kirstine J Bell *Charles Perkins Centre, University of Sydney, Camperdown, Sydney, New South Wales, 2050, Australia.
Sonia Saad *Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney Medical School, University of Sydney, St Leonards, Sydney, New South Wales, Australia.
Bree J Tillett *The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Brisbane, Queensland, 4102, Australia.
Helen M McGuireCharles Perkins Centre, University of Sydney, Camperdown, Sydney, New South Wales, 2050, Australia.
Sara BordbarInfection and Immunity Program, Biomedicine Discovery Institute, Department of Biochemistry, Monash University, Melbourne, Victoria, 3800, Australia.
Yu Anne YapInfection and Immunity Program, Biomedicine Discovery Institute, Department of Biochemistry, Monash University, Melbourne, Victoria, 3800, Australia.
Long T NguyenKolling Institute of Medical Research, Royal North Shore Hospital, Sydney Medical School, University of Sydney, St Leonards, Sydney, New South Wales, Australia.
Marc R WilkinsSystems Biology Initiative, School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, 2052, Australia.
Susan CorleySystems Biology Initiative, School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, 2052, Australia.
Shannon BrodieCharles Perkins Centre, University of Sydney, Camperdown, Sydney, New South Wales, 2050, Australia.
Sussan DuongCharles Perkins Centre, University of Sydney, Camperdown, Sydney, New South Wales, 2050, Australia.
Courtney J WrightCharles Perkins Centre, University of Sydney, Camperdown, Sydney, New South Wales, 2050, Australia.
Stephen TwiggCharles Perkins Centre, University of Sydney, Camperdown, Sydney, New South Wales, 2050, Australia.
Barbara Fazekas de St GrothCharles Perkins Centre, University of Sydney, Camperdown, Sydney, New South Wales, 2050, Australia.
Leonard C HarrisonWalter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Victoria, 3052, Australia.
Charles R MackayInfection and Immunity Program, Biomedicine Discovery Institute, Department of Biochemistry, Monash University, Melbourne, Victoria, 3800, Australia.
Esteban N GurzovSignal Transduction and Metabolism Laboratory, Université libre de Bruxelles, 1070, Brussels, Belgium.
Emma E Hamilton-WilliamsThe University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Brisbane, Queensland, 4102, Australia. e.hamiltonwilliams@uq.edu.au.
Eliana MariñoInfection and Immunity Program, Biomedicine Discovery Institute, Department of Biochemistry, Monash University, Melbourne, Victoria, 3800, Australia. eliana.marino@monash.edu.ORCID 0000-0001-5371-8778
The University of Sydney · AUAustralian Regenerative Medicine Institute · AUThe University of Queensland · AUUNSW Sydney · AUDiscovery Institute · USThe University of Melbourne · AUUniversité Libre de Bruxelles · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundShort-chain fatty acids (SCFAs) produced by the gut microbiota have beneficial anti-inflammatory and gut homeostasis effects and prevent type 1 diabetes (T1D) in mice. Reduced SCFA production indicates a loss of beneficial bacteria, commonly associated with chronic autoimmune and inflammatory diseases, including T1D and type 2 diabetes. Here, we addressed whether a metabolite-based dietary supplement has an impact on humans with T1D. We conducted a single-arm pilot-and-feasibility trial with high-amylose maize-resistant starch modified with acetate and butyrate (HAMSAB) to assess safety, while monitoring changes in the gut microbiota in alignment with modulation of the immune system status.

resultsHAMSAB supplement was administered for 6 weeks with follow-up at 12 weeks in adults with long-standing T1D. Increased concentrations of SCFA acetate, propionate, and butyrate in stools and plasma were in concert with a shift in the composition and function of the gut microbiota. While glucose control and insulin requirements did not change, subjects with the highest SCFA concentrations exhibited the best glycemic control. Bifidobacterium longum, Bifidobacterium adolescentis, and vitamin B7 production correlated with lower HbA1c and basal insulin requirements. Circulating B and T cells developed a more regulatory phenotype post-intervention.

conclusionChanges in gut microbiota composition, function, and immune profile following 6 weeks of HAMSAB supplementation were associated with increased SCFAs in stools and plasma. The persistence of these effects suggests that targeting dietary SCFAs may be a mechanism to alter immune profiles, promote immune tolerance, and improve glycemic control for the treatment of T1D.

trial registrationACTRN12618001391268. Registered 20 August 2018, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375792 Video Abstract.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Gastrointestinal MicrobiomeMicrobiotaAnimalsDietary SupplementsFatty Acids, VolatileHumansMiceFatty Acids, VolatileAutoimmunityDietary-metabolitesImmune regulationMicrobiotaSCFAsType 1 diabetes

Identifiers

PMID35045871
PMCPMC8772108
OpenAlexW4220795584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.